CONFIDENTIAL TREATMENT Amgen USA, Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 March 22, 2007 805-447-1000
Exhibit 10.4
| CONFIDENTIAL TREATMENT |
|
|||
| Amgen USA, Inc. | ||||
| Xxx Xxxxx Xxxxxx Xxxxx | ||||
| Xxxxxxxx Xxxx, XX 00000-0000 | ||||
|
March 22, 2007
|
805-447-1000 | |||
| xxx.xxxxx.xxx |
Fresenius Medical Care Holdings, Inc.
000 Xxxxxx Xxxxxx
Xxxxxxx, XX 00000
Attn: Xxxxxx XxXxxxx
Re: Amendment No. 3 to Sourcing & Supply
Agreement No. 200600447 dated October 1, 2006
Dear Xx. XxXxxxx:
This letter has been written to evidence the agreement reached
by Amgen USA Inc. (“Amgen”) and Fresenius Medical Care
Holdings, Inc. (“FMCH”) to modify and formally amend
the above-referenced Agreement (the “Agreement”) by
and between Amgen and FMCH for the purchase of
EPOGEN®
and
Aranesp®
effective October 1, 2006. Unless otherwise specifically
defined in this letter, each term used herein shall have the
meaning assigned to such term in the Agreement.
[*]
[*]
If you have any questions or comments, please feel free to
contact your Account Manager, Xxxxx Xxxxx at
(000) 000-0000
xxx 00000. We look forward to receiving a signed copy of this
amendment letter.
Sincerely,
AMGEN USA, INC.
Xxxx Xxxxxxxx
Executive Director, Pricing & Contracts
| Agreement No. 200600447 — Amend No. 3 | Ver. FMCHA3_032207f.DOC |
| ACIS 10518 | Fax No. 000-000-0000 |
1
CONFIDENTIAL
TREATMENT
ACKNOWLEDGED AND AGREED:
Fresenius Medical Care Holdings, Inc.
/s/ Xxxxxx
X. Xxxxxxxx
Name: Xxxxxx X. Xxxxxxxx
| Title: | Executive Vice President |
Date: Xxxxx 00, 0000
Xxxxx Inc.
/s/ Xxxxx
Xxxxxx
Name: Xxxxx Xxxxxx
| Title: | Vice President and General Manager |
Date: April 23, 2007
| cc: | Amgen Inc. General Counsel |
Xxxxx Xxxxx
Fresenius Medical Care Holdings, Inc. — General Counsel
***
(see attached file: FMCHA3_Addendum D_032207F)
| Agreement No. 200600447 — Amend No. 3 | Ver. FMCHA3_032207f.DOC |
| ACIS 10518 | Fax No. 000-000-0000 |
2
CONFIDENTIAL TREATMENT
***
